超大分割全乳放疗的心脏安全性:SAFE-FORWARD 前瞻性观察队列研究结果
12 个月时无患者达到预设亚临床心肌损伤标准,3D-LVEF、LV-GLS、3D-RVEF 和 RV-FWLS 均无显著变化,支持该方案的心脏安全性。
要点
- 26 Gy/5 次全乳放疗后 12 个月无患者出现亚临床心肌功能损伤。
- 左乳放疗者 12 个月 LV-EDVI 轻度升高,但与剂量学参数无相关性。
- 平均心脏剂量 0.73 Gy(左乳 0.94 Gy),无 ≥3 级不良事件。
核心结论
- 采用 FAST-Forward 方案的超大分割全乳放疗未导致早期亚临床心肌功能障碍,支持该方案的心脏安全性。
研究设计与样本
- 主要终点为 12 个月时至少一项参数较基线下降 ≥10%:3D-LVEF、3D-RVEF、LV-GLS 或 RV-FWLS。
- 超声心动图于基线及放疗后 2、6、12 个月进行,并勾画心脏亚结构做剂量学相关性分析。
主要发现
- 无患者达到预设亚临床心肌损伤标准。
- 平均 3D-LVEF 基线 64.1%(±3.1),12 个月 63.1%(±2.9),p=0.97。
- LV-GLS 从基线 -20.5%(±1.8)至 12 个月 -20.3%(±1.6),p=0.34。
- 3D-RVEF 和 RV-FWLS 随访期间无变化。
- 左乳放疗者 12 个月 LV-EDVI 轻度但统计学显著升高,与剂量学参数无相关性。
关键数值与推荐
- 亚临床心肌损伤定义:12 个月时 3D-LVEF、3D-RVEF、LV-GLS 或 RV-FWLS 中至少一项较基线下降 ≥10%。
- 平均心脏剂量 0.73 Gy,左乳病例为 0.94 Gy。
- 急性毒性最常见为 1 级放射性皮炎(32%)和乏力(28%),无 ≥3 级不良事件。
- 中位随访 48 个月时全部患者存活,报告 1 例同侧和 3 例对侧乳腺事件。
临床怎么用
- 26 Gy/5 次全乳放疗未观察到早期亚临床心肌功能损害,可作为支持该方案心脏安全性的前瞻性证据。
- 左乳放疗后 LV-EDVI 轻度升高且与剂量学参数无关,提示仍需关注左侧放疗的长期心脏影响。
- 研究结果可为心脏肿瘤学随访策略提供参考。
局限性
- 原文未报告对照组或随机比较。
- LV-EDVI 升高与剂量学参数无相关性,机制未明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Ultra-hypofractionated whole breast irradiation (WBI) following breast-conserving surgery (BCS) is increasingly adopted as standard of care. However, its potential impact on subclinical myocardial function remains poorly characterised. The SAFE-FORWARD study (NCT04842409) prospectively investigated early cardiac effects of the 26 Gy in five fractions regimen using advanced echocardiographic techniques. MATERIALS AND METHODS: Fifty women with early-stage breast cancer (median age 67 years) were enrolled and received postoperative WBI to 26 Gy in five fractions. The primary endpoint was the detection of subclinical myocardial impairment at 12 months, defined as a ≥ 10 % decline from baseline in at least one of the following parameters: three-dimensional left or right ventricular ejection fraction (3D-LVEF, 3D-RVEF), left ventricular global longitudinal strain (LV-GLS), or right ventricular free wall longitudinal strain (RV-FWLS). Echocardiography was performed at baseline, and at 2, 6, and 12 months post-WBI. Cardiac substructures were delineated for dosimetric correlation. Adverse events were recorded using CTCAE v5.0. RESULTS: No patient met the predefined criteria for subclinical myocardial impairment. Mean baseline 3D-LVEF was 64.1 % (±3.1) and remained stable at 12 months (63.1 %, ±2.9; p = 0.97). LV-GLS showed no significant change from baseline (-20.5 % ± 1.8) to 12 months (-20.3 % ± 1.6; p = 0.34). 3D-RVEF and RV-FWLS remained unchanged throughout follow-up. A modest but statistically significant increase in LV end-diastolic volume index (LV-EDVI) was observed at 12 months in patients receiving left-sided WBI, without correlation to dosimetric parameters. Mean heart dose was 0.73 Gy (0.94 Gy for left-sided cases). No grade ≥ 3 adverse events occurred. The most common acute toxicities were grade 1 radiodermatitis (32 %) and fatigue (28 %). At 48 months' median follow-up, all patients were alive, with one ipsilateral and three contralateral breast events reported. CONCLUSION: Ultra-hypofractionated WBI using the FAST-Forward schedule was not associated with early subclinical myocardial dysfunction. These prospective findings support the cardiac safety of this regimen and may inform future cardio-oncology surveillance strategies.
引用
- Salvestrini V, Marrazzo L, Barletta G, et al. Cardiac safety of ultra-hypofractionated whole breast irradiation: Results from the SAFE-FORWARD observational prospective cohort study. Radiother Oncol. 2025. PMID: 41205701. doi:10.1016/j.radonc.2025.111267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。